Quest Diagnostics (DGX) Common Equity (2009 - 2026)

Quest Diagnostics has reported Common Equity for 18 years, with the latest figure at $7.8 billion in Q2 2026.

• Quarterly Common Equity rose 7.63% year-over-year to $7.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.8 billion (up 7.63% YoY) and the FY2025 annual result came in at $7.2 billion, up 5.77% from the prior year.
• Common Equity climbed to $7.8 billion in Q2 2026 per DGX's latest filing, from $7.7 billion in the prior quarter.
• Over five years, Common Equity peaked at $7.8 billion in Q2 2026 and troughed at $5.9 billion in Q4 2022.
• A 5-year average of $6.7 billion and a median of $6.6 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity decreased 8.53% in 2022, then gained 10.11% in 2026.
• Over 5 years, Common Equity stood at $5.9 billion in 2022, then rose by 6.95% to $6.3 billion in 2023, then climbed by 7.43% to $6.8 billion in 2024, then rose by 5.77% to $7.2 billion in 2025, then gained by 8.51% to $7.8 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $7.8 billion, $7.7 billion, and $7.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.